Immune regulation
Thymulin is produced by the thymus, an organ central to T-cell development and immune coordination.
Explore the research →THYMIC & IMMUNE SIGNALLING
Thymulin
A thymus-linked hormone that has attracted interest around immune balance, inflammation and the way immune function changes with age.
Thymic functionImmune signallingInflammation
Established human biology; treatment evidence remains experimentalHuman studies have measured circulating thymulin and its relationship with endocrine function, while therapeutic work is still largely preclinical.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Thymulin?
Thymulin sits at an interesting crossroads between the thymus, the immune system and hormone signalling. Because thymic function changes with age, it has attracted interest around immune balance, inflammation and the wider biology of ageing.
Inflammation
Experimental work suggests thymulin-related signalling can influence inflammatory responses.
Explore the research →Ageing & thymic function
Thymulin levels and thymic activity change across the lifespan.
Explore the research →Neuroendocrine links
Growth hormone, thyroid hormones and other endocrine signals interact with thymulin production.
Explore the research →THE SCIENCE BIT
A thymic peptide that needs zinc to be active.
Thymulin is a nine-amino-acid thymic peptide whose biological activity depends on zinc binding. The peptide and the metal together form the active hormonal complex.
Research connects this complex with T-cell biology and communication between the immune and endocrine systems. That zinc dependence is normal chemistry, not evidence that adding thymulin or zinc improves immunity in everyone.
See the studies & trials →- Peptide + zinc
- The active complex
- T cells
- Immune-development research
- Endocrine links
- Thymus–hormone communication
How this connects to the research
Human physiology is established more clearly than administered-treatment benefit.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Thymulin connects with the body
These are the tissues and biological systems behind the interest in Thymulin.
- Thymus
- Natural production.
- Immune cells
- T-cell-related activity.
- Endocrine systems
- Bidirectional signalling.
The research behind the interest
Immune regulation
Thymulin is produced by the thymus, an organ central to T-cell development and immune coordination.
Human observational work confirms circulating thymulin responds to endocrine state, but administered thymulin has not been established as an immune treatment.
Established biology · experimental treatmentExplore the studies →Inflammation
Experimental work suggests thymulin-related signalling can influence inflammatory responses.
Most therapeutic anti-inflammatory findings come from laboratory and animal research rather than controlled human trials.
Preclinical evidenceExplore the studies →Ageing & thymic function
Thymulin levels and thymic activity change across the lifespan.
That makes it relevant to ageing biology, but there is no demonstrated anti-ageing treatment effect from thymulin administration.
Human biology · efficacy unprovenExplore the studies →Neuroendocrine links
Growth hormone, thyroid hormones and other endocrine signals interact with thymulin production.
These relationships help explain scientific interest without proving that supplementing thymulin improves hormone balance.
Human mechanistic evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableThe thymus-neuroendocrine axis and thymulin ↗
Human and experimental literature
Thymulin is a zinc-dependent thymic hormone with immune and neuroendocrine activity.
Influence of growth hormone on thymic endocrine activity in humans ↗
Children with growth-hormone deficiency and healthy controls
Circulating thymulin was lower in GH-deficient children and changed after GH exposure.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
Human studies measure endogenous thymulin and endocrine relationships.
✓
Clinical efficacyEarly
1/5 evidence depth
No established therapeutic efficacy programme supports routine thymulin treatment.
◇
Safety evidenceLimited
2/5 evidence depth
A modern administered-product safety dataset is lacking.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Substantial mechanistic and animal literature explores immune and inflammatory effects.
HOW TO READ THESE SCORESStrong preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Thymulin research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Thymic function
RESEARCH AREA 02Immune signalling
RESEARCH AREA 03Inflammation
RESEARCH AREA 04Neuroendocrine biology
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Thymulin
Interest centres on immune ageing, inflammation and thymic function, but administered thymulin remains experimental.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Immune resilience
Interest centres on remaining well through periods of stress or recovering after illness. Thymic biology explains why the peptide attracts attention, but it does not establish fewer infections from taking it.
- What makes a report informative
- A defined illness pattern and meaningful clinical outcomes.
- What can muddy the picture
- Exposure, season and normal recovery can change how often someone feels unwell.
Inflammatory balance
People are interested in less inflammatory burden rather than simply greater immune activity. The mechanism is more nuanced than an immune-boosting label suggests.
- What makes a report informative
- A specific condition or symptom rather than a general immune score.
- What can muddy the picture
- Laboratory signalling findings are not proof of clinical symptom relief.
Resilience with age
Age-related thymic changes attract preventive interest in maintaining immune function. That motivation is different from evidence that treatment improves healthspan.
- What makes a report informative
- Functional and clinical outcomes beyond the ageing hypothesis.
- What can muddy the picture
- Endogenous thymulin biology cannot establish benefits of a manufactured product.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Immune regulation
Human observational work confirms circulating thymulin responds to endocrine state, but administered thymulin has not been established as an immune treatment.
Evidence context: Established biology · experimental treatment
Inflammation
Most therapeutic anti-inflammatory findings come from laboratory and animal research rather than controlled human trials.
Evidence context: Preclinical evidence
Ageing & thymic function
That makes it relevant to ageing biology, but there is no demonstrated anti-ageing treatment effect from thymulin administration.
Evidence context: Human biology · efficacy unproven
Neuroendocrine links
These relationships help explain scientific interest without proving that supplementing thymulin improves hormone balance.
Evidence context: Human mechanistic evidence
The biological rationale
Thymulin is a nine-amino-acid thymic peptide whose biological activity depends on zinc binding. The peptide and the metal together form the active hormonal complex.
Research connects this complex with T-cell biology and communication between the immune and endocrine systems. That zinc dependence is normal chemistry, not evidence that adding thymulin or zinc improves immunity in everyone.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
No validated therapeutic thymulin dose or consumer protocol has been established.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Human biomarker and preclinical context
No established administered human regimenHuman measurements of thymulin activity do not establish a treatment amount. A fixed-dose clinical course cannot be derived from the thymus biology literature. Keep amounts manual and tied to an independently specified record.
Form and route: Laboratory and endogenous-hormone research
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
The biology is clearer than the treatment profile
What the current evidence saysEndogenous thymulin is part of normal physiology, but that does not establish the safety of manufactured thymulin products, repeated administration or long-term exposure.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
6 sourcesSources used on this profile
Original publicationThe thymus-neuroendocrine axis and thymulinJournal / DOI ↗Bibliographic recordThe thymus-neuroendocrine axis and thymulinPubMed ↗Original publicationInfluence of growth hormone on thymic endocrine activity in humansJournal / DOI ↗Bibliographic recordInfluence of growth hormone on thymic endocrine activity in humansPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesDrugs@FDA ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
Thymulin is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.